NewLimit Raises $435 Million to Launch Liver Medicine Clinical Trial

Longevity Startup NewLimit Secures $435 Million to Advance Liver Regeneration Therapy

Longevity biotechnology company NewLimit has announced a landmark $435 million Series C funding round, positioning itself to initiate its first clinical trial for a liver-targeted therapy. The financing, led by Founders Fund and supported by Thrive Capital, Lilly Ventures and tech entrepreneurs Nat Friedman and Daniel Gross, underscores growing investor confidence in epigenetic reprogramming as a frontier for age-related disease intervention.

Key Clinical Takeaways:

• NewLimit’s $435 million funding will accelerate clinical development of liver regeneration therapies using epigenetic reprogramming.
• The company plans to launch trials targeting alcohol-related liver disease, a condition linked to 15% of global mortality from cirrhosis.
• Epigenetic reprogramming aims to reverse cellular aging by resetting DNA methylation patterns, a mechanism validated in preclinical models.

Funding Milestone and Strategic Direction

NewLimit, founded in 2021 by Coinbase CEO Brian Armstrong and co-founded by stem cell biologist Jacob Kimmel, has now raised $610 million across three funding rounds since 2025. The latest Series C round follows a $130 million Series B in May 2025 and a $45 million raise in October 2025. The company’s approach focuses on “epigenetic reprogramming,” a process that reverses age-associated DNA methylation changes to restore cellular function.

According to the STAT+ report, the funding will prioritize advancing a lead program targeting liver regeneration. “Our goal is to demonstrate that epigenetic reprogramming can reverse functional decline in aged liver cells,” said Kimmel, who previously led research on cellular reprogramming at the Salk Institute.